Psoriatic arthritis
Conference Coverage
‘Loss-frame’ approach makes psoriasis patients more agreeable to treatment
Explaining possible outcomes without treatment was more effective in getting patients to agree to treatment than was messaging that focused on the...
Conference Coverage
TNF inhibitors may dampen COVID-19 severity
New findings from the COVID-19 Global Rheumatology Alliance Registry.
From the Journals
Psoriasis patients with mental illness report lower satisfaction with physicians
Bettering the experience of patients with mental health comorbidities through a positive and supportive communication style could potentially...
Commentary
Advice on treating rheumatic diseases from a COVID-19 epicenter
Hospital for Special Surgery rheumatologists discuss their approach to caring for patients with rheumatic diseases within their practice during...
Guidelines
ACR gives guidance on rheumatic disease management during pandemic
When COVID-19 is suspected, rheumatic disease patients may continue their hydroxychloroquine but other rheumatic disease treatments may need to be...
Conference Coverage
Biologics better solo than with methotrexate in psoriatic arthritis
Ustekinumab or a tumor necrosis factor inhibitor are better used alone than with methotrexate in the treatment of psoriatic arthritis.
From the Journals
Case series suggests biologics, JAK inhibitors safe during pandemic
Investigators saw no increase in hospitalizations versus the general population in New York City.
Feature
Latest data on COVID-19 patients with rheumatic diseases revealed in registry
Data for a total of 583 COVID-19 patients have now been made available.
Conference Coverage
Differentiating hypersensitivity reactions to monoclonal antibodies
MAUI, HAWAII – Who to send to the allergist for desensitization.
From the Journals
Financial incentives affect the adoption of biosimilars
Adoption of infliximab biosimilars proceeded more slowly at an academic medical center than at a neighboring VAMC, where financial incentives to...
Feature
‘We’re in great distress here,’ infusion center CMO says
Thrivewell is also deploying a mobile infusion unit to recovered COVID-19 patients who require an infusion for their autoimmune disease.